CD274 and cancer: Although the combination of nivolumab and ipilimumab has clearly demonstrated improvement in progression-free survival (PFS) and overall survival (OS) over nivolumab alone in metastatic melanoma (particularly in programmed death ligand 1 [PD-L1]–negative and BRAF [OMIM 164757] mutation–positive melanoma),1,2 its comparative efficacy over nivolumab monotherapy in other advanced cancers has not been well established.